(Q57392736)

7

object named as

Rhea N. Coler

0 references

author name string

Iván D. Vélez

1

0 references

Katherine Gilchrist

2

0 references

Sofía Martínez

3

0 references

José R. Ramírez-Pineda

4

0 references

Jill A. Ashman

5

0 references

Fabiana P. Alves

6

0 references

Lisa Y. Bogatzki

8

0 references

Stuart J. Kahn

9

0 references

Anna Marie Beckmann

10

0 references

Steven G. Reed

12

0 references

Franco M. Piazza

Leishmaniasis and poverty

13

0 references

language of work or name

English

0 references

publication date

December 2009

0 references

published in

Vaccine

0 references

volume

28

0 references

issue

2

0 references

page(s)

329-337

0 references

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.045

Control of neglected tropical diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.045

Leishmaniasis: current situation and new perspectives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.045

The neglected tropical diseases of Latin America and the Caribbean: a review of disease burden and distribution and a roadmap for control and elimination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.045

Failure of a killed Leishmania amazonensis vaccine against American cutaneous leishmaniasis in Colombia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.045

Leishmaniasis: current treatment and prospects for new drugs and vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.045

Controlled field trials of a vaccine against New World cutaneous leishmaniasis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.045

Putting endotoxin to work for us: monophosphoryl lipid A as a safe and effective vaccine adjuvant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.045

Protective efficacy of a tandemly linked, multi-subunit recombinant leishmanial vaccine (Leish-111f) formulated in MPL adjuvant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.045

Taking toll: lipid A mimetics as adjuvants and immunomodulators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.045

Development of a leishmaniasis vaccine: the importance of MPL.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.045

Immunization with a polyprotein vaccine consisting of the T-Cell antigens thiol-specific antioxidant, Leishmania major stress-inducible protein 1, and Leishmania elongation initiation factor protects against leishmaniasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.045

Surrogate markers of immunity to Leishmania major in leishmanin skin test negative individuals from an endemic area re-visited

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.045

Long-term follow-up of patients with Leishmania (Viannia) braziliensis infection and treated with Glucantime

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.045

T helper (h)1/Th2 and Leishmania: paradox rather than paradigm

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.045

The immunology of susceptibility and resistance to Leishmania major in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.045

Comparison of the immune profile of nonhealing cutaneous Leishmaniasis patients with those with active lesions and those who have recovered from infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.045

Determination of the cytokine profile in American cutaneous leishmaniasis using the polymerase chain reaction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.045

Cytokine patterns in the pathogenesis of human leishmaniasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.045

Th1/Th2 immune responses are associated with active cutaneous leishmaniasis and clinical cure is associated with strong interferon-gamma production.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.045

Immune response measured in human volunteers vaccinated with autoclaved Leishmania major vaccine mixed with low dose of BCG.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.045

Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.045

Multiple-cytokine-producing antiviral CD4 T cells are functionally superior to single-cytokine-producing cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.045

Responses to Montenegro antigen after immunization with killed Leishmania promastigotes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.045

Immunotherapy versus chemotherapy in localised cutaneous leishmaniasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.045

Immune response in healthy volunteers vaccinated with killed leishmanial promastigotes plus BCG. I: Skin-test reactivity, T-cell proliferation and interferon-gamma production

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.045

Immune response in healthy volunteers vaccinated with BCG plus killed leishmanial promastigotes: antibody responses to mycobacterial and leishmanial antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.045

Safety and immunogenicity of a killed Leishmania (L.) amazonensis vaccine against cutaneous leishmaniasis in Colombia: a randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.045

Field trial of a vaccine against New World cutaneous leishmaniasis in an at-risk child population: safety, immunogenicity, and efficacy during the first 12 months of follow-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.045

Field trial of a vaccine against new world cutaneous leishmaniasis in an at-risk child population: how long does protection last?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.045

Safety, immunogenecity, and efficacy of an autoclaved Leishmania amazonensis vaccine plus BCG adjuvant against New World cutaneous leishmaniasis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.045

Randomised vaccine trial of single dose of killed Leishmania major plus BCG against anthroponotic cutaneous leishmaniasis in Bam, Iran.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.045

A randomised, double-blind, controlled trial of a killed L. major vaccine plus BCG against zoonotic cutaneous leishmaniasis in Iran

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.045

Autoclaved Leishmania major vaccine for prevention of visceral leishmaniasis: a randomised, double-blind, BCG-controlled trial in Sudan.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.045

Efficacy of killed whole-parasite vaccines in the prevention of leishmaniasis: a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.045

Leishmania vaccines: progress and problems.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.045

Development of a safe live Leishmania vaccine line by gene replacement.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.045

Dichotomy of the human T cell response to Leishmania antigens. II. Absent or Th2-like response to gp63 and Th1-like response to lipophosphoglycan-associated protein in cells from cured visceral leishmaniasis patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.045

Prophylactic immunization against experimental Leishmania donovani infection by use of a purified protein vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.045

Expression cloning of a protective Leishmania antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.045

Cloning of genes and expression and antigenicity analysis of the Leishmania infantum KMP-11 protein.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.045

Immune responses induced by a Leishmania (Leishmania) amazonensis recombinant antigen in mice and lymphocytes from vaccinated subjects.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.045

Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.045

Second-generation vaccines against leishmaniasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.045

Vaccines for leishmaniasis in the fore coming 25 years.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.045

Recombinant vaccinia viruses expressing GP46/M-2 protect against Leishmania infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.045

inferred from DOI database lookup

7 January 2021

based on heuristic

Protective vaccination with promastigote surface antigen 2 from Leishmania major is mediated by a TH1 type of immune response

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.045